ARM Member Profiles

GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas. Invented and developed by a world-class team of scientists in the lab of George Church, Ph.D., at the Wyss Institute of Harvard University, GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome™, integrates the latest advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.